Heterogeneity in the etiopathology of autism spectrum disorders (ASD) limits the development of generic remedies, requires individualistic and patient-specific research. Recent progress in human-induced pluripotent stem cell (iPSC) technology provides a novel platform for modeling ASDs for studying complex neuronal phenotypes. In this study, we generated telencephalic induced neuronal (iN) cells from iPSCs derived from an ASD patient with a heterozygous point mutation in the DSCAM gene. The mRNA of DSCAM and the density of DSCAM in dendrites were significantly decreased in ASD compared to control iN cells. RNA sequencing analysis revealed that several synaptic function-related genes including NMDA receptor subunits were downregulated in ASD iN cells. Moreover, NMDA receptor (R)-mediated currents were significantly reduced in ASD compared to control iN cells. Normal NMDA-R-mediated current levels were rescued by expressing wild-type DSCAM in ASD iN cells, and reduced currents were observed by truncated DSCAM expression in control iN cells. shRNA-mediated DSCAM knockdown in control iN cells resulted in the downregulation of an NMDA-R subunit, which was rescued by the overexpression of shRNA-resistant DSCAM. Furthermore, DSCAM was co-localized with NMDA-R components in the dendritic spines of iN cells whereas their co-localizations were significantly reduced in ASD iN cells. Levels of phospho-ERK1/2 were significantly lower in ASD iN cells, suggesting a potential mechanism. A neural stem cell-specific Dscam heterozygous knockout mouse model, showing deficits in social interaction and social memory with reduced NMDA-R currents. These data suggest that DSCAM mutation causes pathological symptoms of ASD by dysregulating NMDA-R function.

Molecular Psychiatry (2021) 26:7538–7549; https://doi.org/10.1038/s41380-021-01216-9

INTRODUCTION

Autism spectrum disorder (ASD) refers to a group of complex neurodevelopmental disorders characterized by persistent difficulties with social communication and social interaction, restricted and repetitive behavior (including sensory behaviors), activities, or interests, and early childhood manifestation of symptoms [1] and poses a serious threat to a patient’s ability to harmoniously adapt to society. Although ASD is clearly defined by diagnostic criteria, the levels of severity and penetration may vary among individuals. The complexity and heterogeneity of ASD pathogenesis, along with the lack of a proper human cellular model system, makes it difficult to explore the pathophysiological mechanisms of ASD in human development. Nonetheless, recent progress in human-induced pluripotent stem cell (iPSC) technology provides a novel platform for modeling neurodevelopmental or psychiatric disorders in patients with monogenic or idiopathic mutations, and provides access to patient-specific cells for drug discovery and personalized medicine [2, 3]. Moreover, recent reports highlight the rational use of iPSC-derived neurons to model ASDs in the study of complex neuronal phenotypes [4, 5]. Genes for many synaptic proteins, such as Shank, have been identified as ASD candidate genes, paving the way for studies on ASD pathogenesis using cellular and animal models [6-9]. Among the synaptic proteins associated with ASD, N-methyl-D-aspartate receptor (NMDA) receptors (Rs) are important in neuronal differentiation and synaptic plasticity in several brain regions including the hippocampus and cortex [14, 15].
Variants in the Down syndrome cell adhesion molecule (DSCAM) gene exist in many ASD patients [16–20], suggesting that DSCAM is an ASD-related gene. DSCAM has been implicated in the development of the human central and peripheral nervous system in the context of axon targeting, dendrite branching, and synapse formation [21, 22]. DSCAM is involved in self-avoidance, a mechanism in which the neuronal processes repel each other during dendritic arborization and axonal branching for uniform distribution of axonal and dendritic processes during synapse formation [23]. Electrophysiological recordings at the glutamatergic neuromuscular junction of Drosophila showed smaller and more frequent miniature EJP [24], suggesting that altered Dscam expression levels may cause impairment of synaptic transmission. In Aplysia, Dscam mediates the remodeling of glutamate Rs during de novo and learning-related synaptogenesis [25]. A mouse line with a spontaneous mutation in Dscam (Dscam<sup>−/+</sup>) showed gross morphological changes in brain size and shape [22], as well as a decrease in the thickness of cortical layers and altered dendritic morphology in pyramidal neurons [22]. These mice also exhibit severe hydrocephalus, decreased motor function, and impaired motor learning ability [26]. However, it is unclear whether ASD phenotypes, such as social deficits are replicated in mice deficient for Dscam, and how DSCAM mutations lead to ASD-like cellular phenotypes at the synapse in human-iPSC-derived neuronal models.

In this study, we generated forebrain-like induced neuronal (iN) cells from the iPSCs of an ASD patient with a de novo heterozygous point mutation in the DSCAM gene, predicting a truncated protein expression. We investigated global gene expression, cellular phenotypes, and electrophysiological properties of the iN cells. To determine the role of DSCAM in ASD pathophysiology in vivo, we examined behavioral phenotypes, such as social interactions and repetitive behaviors in Nestin-Dscam<sup>−/+</sup> mice.

MATERIALS AND METHODS
Patient description
The proband, a 12-year-old boy, was born at 39 weeks' gestation by spontaneous vaginal delivery with a birth weight of 3.5 kg after an uncomplicated pregnancy. He manifested autistic features before 36 months of age. His Autism Diagnostic Observation Schedule-2 (ADOS-2) testing demonstrated a total score of 15 (social affect score, 14; restricted and repetitive behavior score, 1) well within the range of an autism diagnosis at age five. His Autism Diagnostic Interview-Revised (ADI-R) scores were also above the autism diagnostic cutoffs. In addition, he demonstrated severe sleep problems and a significantly high level of anxiety, with crying and screaming both at school and at home, particularly with his mother. He has intellectual disability and obesity at a weight of 79 kg and height of 165 cm. He has received early intervention since the age of 3 years old, but his behavior problems have continued throughout his childhood.

Generation of iPSCs and neuronal induction from iPSCs
Human-iPSC lines were generated from skin fibroblasts using an integration-free method, as previously described [27]. The passage numbers of the control and ASD iPSC lines used in this study were between 40 and 80. iN cells were generated as described previously [28], with minor modifications. Detailed protocols are described in the Supplementary Information.

RNA sequencing analysis
Total RNA was extracted from the iPSC-derived control and ASD iN cells. The quality and integrity of the extracted total RNA were assessed using BioAnalyzer and the standard Illumina sequencing system protocol (TruSeq RNA sample preparation kit v2) was used to make libraries for RNA sequencing. About 300-bp-long fragments were isolated using gel electrophoresis; they were then amplified by PCR and sequenced on Illumina HiSeq X platform in the paired-end sequencing mode (2 × 150 bp reads). Bioinformatic analysis was performed as described previously [29]. Briefly, raw sequencing reads were aligned to the human genome and differential gene expression analysis was conducted using the DESeq2 method [30] and genes with at least 1.5-fold changes between groups at a false discovery rate of 5% were defined as differentially expressed genes. The Metascape tool [31] was used for functional annotations for the differentially expressed genes identified.

Quantitative real-time PCR
Total mRNA was extracted and cDNA was synthesized as previously described [32]. To analyze gene expression changes between control and ASD iPSCs or iN cells, quantitative RT-PCR was performed using specific primers, which are presented in Supplementary Table 3.

Knockdown experiments
For knockdown experiments, pSuper-dTomato or pSuper-H1-hDSCAM shRNA-dTomato were transfected in 5–6-week-old control iN cells and fixed with 4% paraformaldehyde 48 h after the transfection. Regarding rescue experiments, pSuper-dTomato or pSuper-H1-hDSCAM shRNA-dTomato constructs together with pcDNA3-hDSCAM(R)-FLAG construct were co-transfected into 5–6-week-old control iN cells (pSuper-dTomato: 2.5 μg, pSuper-H1-hDSCAM shRNA-dTomato: 2.5 μg, pcDNA3-hDSCAM(R)-FLAG: 5 μg. Lipofectamine 2000 or 3000: 4.6 μl per well of 24-well plate) and the transfection mixture was then replaced with culture media 6 h after the transfection. After a 48-h incubation, the iN cells were fixed with 4% paraformaldehyde for immunocytochemical analysis.

Immunocytochemistry
Standard immunocytochemistry was performed as described previously [33, 34]. Detailed experimental procedures with antibody information are described in the Supplementary Information.

Proximity ligation assay (PLA)
Generic in situ PLA was performed using a Duolink kit (Sigma-Aldrich, DUO92101) according to the manufacturer’s instructions with minor changes. Detailed protocols are given in the Supplementary Information. PLA reactions were followed by immunocytochemistry with the addition of primary antibodies (PSD-95, NeuroMab, 75-028) and then fluorophore-conjugated secondary antibodies.

Western blot analysis
Western blot analysis was performed as previously described [35]. Further details are provided in the Supplementary Information.

Electrophysiology
Whole-cell patch-clamp recordings from iN cells and the anterior cingulate cortex (ACC) layer 2/3 cortical neurons from mouse brain slices were performed as previously described [36]. More details are provided in the Supplementary Information.

Generation of Nestin-Dscam<sup>−/+</sup> mice
Nestin-Dscam<sup>−/+</sup> mice were produced by crossing Nestin-Cre mice with Dscam floxed exon 1 mice (B6.129P2-Dscam<sup>1flox</sup>/Kzy, RIKEN BioResource Research Center) [37]. Mice were bred in a room with a 12–12 h light-dark cycle, and food and water were provided ad libitum. All behavioral experiments were conducted during the light phase and were approved by the Institutional Animal Care and Use Committees at Seoul National University (SNU-200109-2).

Behavioral analyses
Behavioral analyses were performed as previously described [38–40] and are provided in detail in the Supplementary Information.

Statistical analysis
We did not use any statistical methods to pre-determine the sample sizes, but our sample sizes were similar to those reported in previously published papers [28, 41]. All data were analyzed by Prism 8 software (GraphPad). Either unpaired t-test or Mann–Whitney test after normality tests was conducted to compare two different groups. One-way ANOVA or Kruskal–Wallis test were used to compare the means of more than two groups. Two-way (repeated measures) ANOVA was used to analyze the...
mean differences between groups. In all statistical analyses, significance was shown as $p<0.05$, $**p<0.01$, $***p<0.001$, and $****p<0.0001$. Data are presented as the mean ± SEM.

**RESULTS**

**Clinical features and genetic information of the ASD patient**

The patient (Fig. 1a, black-filled square in the pedigree), a 12-year-old boy, presented the clinical signs of ASD, which emerged at age 3. Subscale totals in the Autism Treatment Evaluation Checklist before medical intervention were above 102, which indicates very severe autism in the 90th percentile (Fig. 1b). Patients with scores less than 50 are within the 30th percentile and are considered to have a good chance of being semi-independent. The patient’s adaptation to nursery school was difficult. His mother described his behavioral disorders, which included incessant restlessness, sleeping and communication disorders, and a lack of speech. To identify genetic mutations in the patient, we performed whole exome sequencing of his four family members and found a single de novo mutation in the DSCAM gene of an ASD patient (II-1). We performed whole exome sequencing on four family members (I-1, I-2, II-1, and II-2). Confirming the identified single nucleotide deletion in the DSCAM gene, the single nucleotide deletion (DSCAM, c.2051del) identified in the ASD patient was validated by Sanger sequencing of the genomic DNA from four family members. The DSCAM transcript, NM_001271534 (RefSeq sequence) with the single nucleotide deletion (c.2051del; cDNA position 2051) is translated into a truncated form of the DSCAM protein due to an early stop codon at amino acid position 684, leucine (pL684X). Other predicted truncation mutations reported previously (Satterstrom et al. [62]) are indicated by blue arrows (IG immunoglobulin domain, FN fibronectin type III domain, TM transmembrane domain, CM cytoplasmic domain). The single nucleotide deletion (c.2051del; cDNA position 2051) is translated into a truncated form of the DSCAM protein due to the introduction of a premature termination codon (L684X), which is located between the immunoglobulin (IG) 7 and 8 domains of DSCAM. Other predicted truncation mutations reported previously (Satterstrom et al. [62]) are indicated by blue arrows (IG immunoglobulin domain, FN fibronectin type III domain, TM transmembrane domain, CM cytoplasmic domain).

**Fig. 1 De novo single nucleotide deletion in the DSCAM gene of an ASD patient and generation and characterization of ASD iN cells.**

a Pedigree of the ASD family. The black-filled symbol represents the ASD patient (II-1). b Autism Treatment Evaluation Checklist (ATEC) score of the ASD patient before intervention. c Whole exome sequencing was performed on four family members (I-1, I-2, II-1, and II-2). Confirmation of the identified single nucleotide deletion in the DSCAM gene. The single nucleotide deletion (DSCAM, c.2051del) identified in the ASD patient was validated by Sanger sequencing of the genomic DNA from four family members. The DSCAM transcript, NM_001271534 (RefSeq sequence) with the single nucleotide deletion (c.2051del; cDNA position 2051) is translated into a truncated form of the DSCAM protein due to an early stop codon at amino acid position 684, leucine (pL684X). d Schematic diagram of the DSCAM protein with the termination site (L684X), which is located between the immunoglobulin (IG) 7 and 8 domains of DSCAM. Other predicted truncation mutations reported previously (Satterstrom et al. [62]) are indicated by blue arrows (IG immunoglobulin domain, FN fibronectin type III domain, TM transmembrane domain, CM cytoplasmic domain). e Timetable of the differentiation procedure of iN cells from iPSCs. The patient (Fig.1a, black-filled square in the pedigree), a 12-year-old boy, presented the clinical signs of ASD, which emerged at age 3. Subscale totals in the Autism Treatment Evaluation Checklist before medical intervention were above 102, which indicates very severe autism in the 90th percentile (Fig.1b). Patients with scores less than 50 are within the 30th percentile and are considered to have a good chance of being semi-independent. The patient’s adaptation to nursery school was difficult. His mother described his behavioral disorders, which included incessant restlessness, sleeping and communication disorders, and a lack of speech. To identify genetic mutations in the patient, we performed whole exome sequencing of his four family members and found a single de novo mutation in the DSCAM gene only in the patient, identified as a single c.2051del (cDNA position 2051) by Sanger sequencing (Fig. 1c). We predicted that the deletion would generate a truncated form of the DSCAM protein due to the introduction of a premature termination codon (L684X) located between immunoglobulin domains 7 and 8 (Fig. 1d).
Generation and characterization of ASD induced neuronal (iN) cells
To investigate the pathophysiological effect of the novel premature termination mutation in the DSCAM gene, patient-specific ASD iPSC lines (ASD#3, ASD#4, and ASD#5) and control iPSC lines (Control#1, Control#2, and Control#3) were generated from skin fibroblasts of the ASD patient and healthy controls (Supplementary Table 1). We also used another control iPSC line (Control#4) which was generated and characterized in a previous study [42]. The ASD and control iPSC colonies showed a typical round morphology, with small, tightly packed cells (Supplementary Fig. 1a). Pluri potency of each iPSC line was validated by alkaline phosphatase activity, immunocytochemistry, and RT-PCR analyses using stem cell markers (Oct3/4, SSEA4, Tra1-60, and Tra1-81), respectively (Supplementary Fig. 1a–d, Supplementary Table 2). Each control or ASD iPSC line displayed a normal karyotype (Supplementary Fig. 2a). All control iPSC (#1, 2, 3, 4) and ASD iPSC (#3, 4, 5) lines tested negative for mycoplasma (Supplementary Fig. 2b).

To examine cellular phenotypes caused by the DSCAM mutation, forebrain-like iN cells were generated from the above iPSCs using previously described protocols [28] with minor modifications (Fig. 1e). The DSCAM mutation was confirmed in each step of the process of fibroblasts to ASD iPSCs to ASD iPSCs-derived iN cells (Supplementary Fig. 2c, Supplementary Table 2). The relative neural differentiation ratio from iPSCs to iN cells was measured by counting TuJ1-immunopositive cells vs. Neurogenin2-expressing (GFP-positive) cells at 2 weeks of glia co-culture, with no difference in the neural differentiation rate between ASD and control iN cells (Fig. 1f, g). We also performed vGlut1 immunostaining with 2-week-old iN cell cultures to check the efficiency of Nggn2-induction and >95% of iN cells expressed vGlut1 (Fig. 1f, g), suggesting that pure glutamatergic iN cells were induced by Nggn2 expression, consistent with a previous report [28]. Next, we examined whether the heterozygous DSCAM mutation affected the DSCAM expression level of ASD iN cells. The mRNA expression of DSCAM was significantly reduced in ASD iN cells as compared to controls (Fig. 1h). The significantly lower expression of the DSCAM protein was detected by immunocytochemistry in the dendrites of ASD iN cells (Fig. 1i, j) as compared to controls, indicating that the single c.2051del (cDNA position 2051) may affect the expression level of DSCAM (Fig. 1h–j).

We next examined axonal or dendritic development in control or ASD iN cells. Thus, we investigated axonal growth in iN cells at day 3 after glia co-culture by visualizing axons with tubulin immunostaining, which lacks a MAP2 signal (Supplementary Fig. 3a). Axonal length was significantly decreased in ASD iN cells as compared to control iN cells (Supplementary Fig. 3b). We also examined dendritic growth at day 6 after glia co-culture. Dendritic complexity as measured by Sholl analyses was unchanged in ASD iN cells as compared to control iN cells (Supplementary Fig. 3c–e). To examine spinogenesis, we examined spines by PSD-95 immunostaining in 5–6-week-old iN cell cultures and observed comparable spine density in both control and ASD iN cells (Supplementary Fig. 6d).

RNA sequencing analysis
To delineate the molecular pathology mechanisms for the identified de novo variants, we performed RNA sequencing analysis and compared the transcriptomic profiles between ASD iN cells (#3) and control iN cells (#1 and #2). A total of 1805 differentially expressed genes (upregulated, 877 and downregulated, 928) were identified (Fig. 2a) and functional annotations analysis using known pathways and gene ontology was conducted to investigate the enriched molecular signatures in the differentially expressed genes. Of note, pathways enriched in downregulated genes in ASD iN cells are related to neuronal processes, such as “trans-synaptic signaling”, “axon development”, “synapse organization”, and “regulation of neuron death” (Fig. 2b, left panel and Fig. 2c). In contrast, pathways or terms related to general developmental processes, such as “extracellular matrix organization” and “elastic fiber formation” are enriched in the upregulated genes in ASD iN cells (Fig. 2b, right panel).

Interestingly, we found that the expression of NMDA-R subunits, such as NR1, NR2B, and NR3A were reduced in ASD iN cells as compared to control iN cells. We performed quantitative RT-PCR to validate the RNA sequencing analysis. Among several synapse-related genes, the components of NMDA-R, NR1, and NR2B, are decreased in ASD iN cells (Fig. 2d, upper panel). Specifically, NR1 showed a more severe decrease than NR2B. Furthermore, the genes related to trans-synaptic signaling, LRRTM1 and SYT6, are also decreased in ASD iN cells as compared to control iN cells (Fig. 2d, bottom panel).

Compromised NMDA currents in ASD iN cells are rescued by exogenous expression of full-length DSCAM
As our transcriptome analyses revealed the reduced expression of NMDA-R subunits and NMDA-R dysfunctions have been implicated in the pathogenesis of ASD, we investigated whether NMDA-R-mediated currents are altered in ASD iN cells. Interestingly, the amplitude of NMDA-R currents (I_NMDA) was significantly decreased in ASD iN cells compared to control iN cells (Fig. 3a). Consistently, the mRNA levels of NMDA-R components (NR1, NR2A and NR2B) were significantly lower in ASD iN cells compared to control iN cells (Fig. 3b). Specifically, NR1 shows severe decrease in ASD iN cells, and we focused on NR1 for followed experiments. The protein levels of NR1, as detected by immunocytochemistry (Fig. 3c, d) and immunoblotting (Fig. 3e, f), were also reduced in ASD iN cells.

In our next experiment, we examined the basic electrical properties of control and ASD iN cells. The resting membrane potential of ASD iN cells was approximately −45 mV at 2 weeks after glia co-culture, similar to that of control iN cells (Supplementary Fig. 4a). Membrane capacitance (Supplementary Fig. 4b) also did not differ between ASD and control iN cells. However, input resistance was significantly decreased in ASD iN cells (Supplementary Fig. 4c). We observed an increase in neuronal excitability in ASD iN cells, with a larger amplitude and shorter half-width of the action potential (Supplementary Fig. 4d–g). In addition, we examined whether the heterozygous DSCAM mutation affected any synaptic properties of ASD iN cells. We analyzed spontaneous synaptic activity by measuring miniature EPSC, with no changes in frequency but with a slight increase in the amplitude of mEPSC in ASD iN cells (Supplementary Fig. 4h, i).

In order to determine whether the truncated form of DSCAM (might be generated by the genetic mutation) affected NMDA-R currents (I_NMDA), we examined NMDA-R current changes upon the expression of either the full-length or truncated form of DSCAM in ASD and control iN cells, respectively. When the truncated form of DSCAM (N-terminal DSCAM) was transfected in control iN cells, a significant decrease in I_NMDA at the +40 and +60 mV holding potentials was observed (Fig. 3g, left panel). In contrast, when the full-length DSCAM was expressed in ASD iN cells, amplitude of I_NMDA at the +40 and +60 mV holding potentials was significantly increased (Fig. 3g, right panel). Expression of NR1 detected by immunocytochemistry was decreased when the truncated form of DSCAM was introduced in control iN cells (Fig. 3h) while it was increased when the full-length DSCAM was expressed in ASD iN cells (Fig. 3h). In addition, when endogenous DSCAM was knocked down by a specific shRNA (Supplementary Fig. 5a), NR1 and DSCAM expression were significantly decreased in the control iN cells (Supplementary Fig. 5b–e). The decreases of both DSCAM and NR1 density were rescued to control levels by the reintroduction of shRNA-resistant DSCAM (DSCAM(R)) in control iN cells in which endogenous DSCAM was knocked down by
shRNA (Supplementary Fig. 5f–i). Consequently, these data suggest that wild-type (WT) DSCAM is essential for proper NR1 expression and normal NMDA-R currents.

Co-localization of DSCAM with NR1 in dendritic spines and pERK1/2 activity is significantly reduced in ASD iN cells

To define how DSCAM affected NMDA-R currents, we examined the co-localization of DSCAM with an NMDA-R subunit, NR1, in iN cells. Immunoreactive (IR) signals for NR1 and DSCAM were widely distributed throughout the cell bodies and dendrites and showed about 50% co-localization in dendrites (Fig. 4a–c, Supplementary Fig. 6). This co-localization between DSCAM and NR1 was significantly reduced in dendrites of ASD iN cells (Fig. 4a–c).

Extracellular signal-regulated kinase (ERK) activity is modulated by NMDA-R activation and is synchronized with NMDA-R currents [43]. To gain insight into the potential downstream consequences of DSCAM and NMDA-R co-localization, we measured phospho-

Fig. 2 Transcriptomic analysis of ASD iN cells. a A volcano plot for differentially expressed genes between ASD and control iN cells. Significantly upregulated genes are represented by red dots and black dots indicate significantly downregulated genes in ASD iN cells. The X-axis is the log2-transformed gene expression in ASD iN cells divided by that in control iN cells. The Y-axis represents the p value (−log10) adjusted by the multiple testing correction. b Gene ontology term and functional pathway enrichments in upregulated (red) genes and downregulated (black) genes in ASD iN cells by Metascape. The adjusted p values of significantly enriched terms or pathways are shown as bar plots (−log10adjP). c Representative heatmaps for the top four enriched terms or pathways (HATs acetylate histones, trans-synaptic signaling, axon development, and synapse organization) for the down downregulated genes in ASD iN cells. d Quantitative RT-PCR analyses of mRNA expression level of NR1, NR2B, LRRTM1, and SYT6 in 3-week-old iN cells. Each gene expression was normalized to GAPDH expression. The NMDA-R components, NR1 and NR2B, are decreased in ASD iN cells. For NR1 [Control: n = 19, ASD: n = 10 (Control#1: n = 5; Control#2: n = 5, Control#3: n = 5, Control#4: n = 4, ASD#3: n = 5, ASD#4: n = 5)], unpaired t-test for right panels (****p < 0.0001). For NR2B [Control: n = 15, ASD: n = 8 (control#1: n = 4, control#2: n = 4, control#3: n = 4, control#4: n = 3, ASD#3: n = 4, ASD#4: n = 4)], unpaired t-test for right panel, *p < 0.05. For LRRTM1 [Control: n = 30, ASD: n = 17 (Control#1: n = 8; Control#2: n = 8, Control#3: n = 8, Control#4: n = 6, ASD#3: n = 8, ASD#4: n = 7, ASD#5: n = 2)], unpaired t-test for right panels, not significant (p = 0.107). For SYT6 [Control: n = 30, ASD: n = 16 (Control#1: n = 8, Control#2: n = 8, Control#3: n = 8, Control#4: n = 6, ASD#3: n = 7, ASD#4: n = 7, ASD#5: n = 2)], unpaired t-test for right panel (**p < 0.01).
ERK levels in ASD and control iN cells. We observed a low level of pERK IR signal (Fig. 4g) and a significant decrease in the pERK/Ngn2 ratio in ASD iN cells as compared to control iN cells (Fig. 4g, h). These results raise the possibility that DSCAM interacts with NMDA-Rs in the spine to regulate the downstream intracellular ERK signaling pathway in control iN cells, but their interactions are reduced in ASD iN cells.

Generation of Nestin-Dscam+/− mice

Recently, variants in the DSCAM gene were identified in many ASD patients [16–20], and several Dscam KO mouse models have been established. However, autistic phenotypes are not yet reported in these mouse models. To examine the effect of Dscam mutation on behavioral phenotypes in vivo, we generated an ASD mouse model by crossing the Nestin-Cre mouse [44] with the floxed Dscam exon 1 mouse [37], which causes the Dscam gene to be heterozygously deleted, specifically in neural stem cells (NSCs) (Supplementary Fig. 8a). Western blot analysis on the ACC, a brain region associated with social behaviors [41, 45], showed that Dscam expression in the heterozygous Nestin-Dscam+/− mice was significantly reduced as compared to WT littermates (Supplementary Fig. 8b). Notably, the body weight of Nestin-Dscam+/− mice was significantly lower compared to WT littermates (Supplementary Fig. 8c).

To examine whether the basal behavior of Nestin-Dscam+/− mice was altered, we used the open-field test (Supplementary Fig. 8d–f). Both WT and Nestin-Dscam+/− mice spent similar time in the center zone (Supplementary Fig. 8d, e), which indicates no change in anxiety-like behavior in the Nestin-Dscam+/− mice. There was also no significant difference in the distance moved between Nestin-Dscam+/− and WT littermates during 30 min in the open-field test (Supplementary Fig. 8f), suggesting that locomotive activity was normal in Nestin-Dscam+/− mice.

Nestin-Dscam+/− mice are impaired in social behaviors and NMDA-R functions

Next, the social interaction behaviors of Nestin-Dscam+/− mice were measured using reciprocal interaction and three-chamber tests [10, 39, 46, 47]. In the reciprocal interaction test, we observed a decreased total interaction time and following time but not nose-poking and sniffing time in Nestin-Dscam+/− mice as compared to WT littermates (Fig. 5a–d). In the three-chamber test, WT mice spent more time with the stranger mouse (stranger 1) than with the object. In contrast, the Nestin-Dscam+/− mice spent less time interacting with the stranger mouse than with the object, suggesting impaired sociability (Fig. 5e). Next, another stranger mouse (stranger 2) was placed in one chamber instead of the object, and the test mouse was allowed to explore the chamber freely. Nestin-Dscam+/− mice showed a decreased level of interest in the stranger 2 mouse as compared to WT mice (Fig. 5f), suggesting a social novelty deficit in Nestin-Dscam+/− mice. Social communication as measured by the ultrasonic vocalization test [48, 49] was not different in Nestin-Dscam+/− mice as compared to WT littermates (Supplementary Fig. 9a, b). Therefore, Nestin-Dscam+/− mice showed reduced sociability and social novelty as compared to WT littermates, which reflects some behavioral characteristics of ASD patients.

An increased level of repetitive behavior is also a feature of ASD [50, 51]. To examine whether the Nestin-Dscam+/− mice showed any repetitive behaviors, we performed the marble burying test and monitored for various repetitive behaviors in the mouse’s home cage. Nestin-Dscam+/− mice and WT littermates showed no performance difference in the marble-burying test (Supplementary Fig. 9c). When we analyzed the time spent on repetitive behaviors, such as self-grooming, digging, and rearing in the home cage, there was no difference between Nestin-Dscam+/− mice and WT littermates (Supplementary Fig. 9d–f).
Finally, we examined the ratio of NMDA-R to AMPA-R-mediated synaptic currents from layer 2/3 pyramidal neurons in the ACC. Consistent with the results from the iN cells derived from our ASD patient (Fig. 5c, d, Supplementary Fig. 4), the NMDA/AMPA ratio was significantly lower in the Nestin-Dscam^−/− mice as compared to WT littermates (Fig. 5g, h), suggesting that NMDA-R hypofunction underlies autistic behaviors found in Nestin-Dscam^−/− mice.

**DISCUSSION**

Although numerous ASD-related genetic variations are reported [52, 53], synaptic dysfunction is suggested as a core mechanism underlying ASD pathophysiology [54, 55]. Among the synaptic proteins associated with ASD, NMDA-R has garnered much attention for its importance in synaptic transmission in the mammalian excitatory synapse [56]. In animal studies, many ASD models with mutations in various genes exhibit NMDA-R dysfunction [10–13]. Mice lacking neuroligin-1 showed reduced NMDA-R function in the hippocampus and striatum [12, 57, 58]. Shank2 mice lacking exons 6 and 7 also display reduced hippocampal NMDA-R function [10]. In addition, pharmacological upregulation of NMDA-R function is suggested to improve ASD symptoms in ASD patients [57, 58] and in mouse models [10, 59–61].

DSCAM is on a short list of 26 genome-wide significant ASD genes in the largest genetic study of ASD to date (Satterstrom et al.; SI Table 2) [62]. All reported ASD cases (n = 5), including the patient in our study, attributed to DSCAM are de novo protein truncated variants. In humans, DSCAM is highly expressed during fetal development (9–16 pcw) especially in brain regions, such as the hippocampus, cerebellum, cerebral cortex, and lateral ventricle (https://www.brainspan.org; Brain Span). On cellular level, DSCAM mRNA is highly expressed in neurons, oligodendrocyte progenitor cells and young oligodendrocytes in human and mouse brain (https://www.brainmaseq.org) [63]. However, how DSCAM mutations actually contribute to the molecular pathogenesis of ASD is largely unknown. Furthermore, little is known about whether DSCAM mutations affect NMDA-R function or not. In this study, for the first time, using forebrain-like neuronal (iN) cells generated from iPSCs of an ASD patient with a de novo mutation in DSCAM, we found a reduction in NR1 density (Control + mRuby: n = 86; Control#1 + mRuby: n = 37, Control#2 + mRuby: n = 17, Control#3 + mRuby: n = 27, Control#4 + mRuby: n = 5, Control + N-terminal DSCAM: n = 65; Control#1 + N-terminal DSCAM: n = 87, Control#2 + N-terminal DSCAM: n = 11, Control#3 + N-terminal DSCAM: n = 16, Control#4 + N-terminal DSCAM: n = 7) and exogenous overexpression of WT full-length DSCAM in ASD iN cells significantly increased NR1 expression (ASD + mRuby: n = 112; ASD#3 + mRuby: n = 69, ASD#4 + mRuby: n = 33, ASD#5 + mRuby: n = 10, ASD + Full-length DSCAM: n = 93; ASD#3 + Full-length DSCAM: n = 36, ASD#4 + Full-length DSCAM: n = 45, ASD#5 + Full-length DSCAM: n = 12). Kruskal–Wallis test for left panel (p < 0.0001) followed by Dunn’s multiple comparisons test (Control#3 + mRuby vs. Control#1 + N-terminal DSCAM, *p < 0.01, ASD#3 + mRuby vs. ASD#4 + N-terminal DSCAM, **p < 0.01, Kruskal–Wallis test for right panel (p < 0.01) followed by Dunn’s multiple comparisons test (Control + mRuby vs. Control#2 + N-terminal DSCAM, ****p < 0.0001, Control#1 + mRuby vs. ASD + mRuby, ******p < 0.0001, Control + mRuby vs. ASD + Full-length DSCAM, ***p < 0.05, ASD + mRuby vs. ASD + Full-length DSCAM, ****p < 0.0001).
DSCAM and NR1 was revealed in the dendrites of control iN cells, which was significantly reduced in ASD iN cells (Fig. 4). Most of this interaction was observed in dendritic spines, as defined by PSD-95 immunostaining. This DSCAM-NR1-PSD-95 tripartite co-localization further strengthens our hypothesis that reduced NMDA-Rs or DSCAM expression impairs the function of NMDA-R in dendritic spines, which in turn could affect NMDA-R currents in ASD iN cells. Exogenous expression of N-terminal DSCAM resulted in reduced NMDA-R currents in control iN lines, whereas full-length DSCAM rescued NMDA-R currents in ASD iN cells. In addition, expression of N-terminal DSCAM caused decreased NR1 expression in control iN cells (Fig. 3g), consistent with our RNA sequencing showing lower level of NMDA-R expression in ASD iN cells (Fig. 2). One possible explanation is that overexpression of the full-length DSCAM overcomes the dominant-negative role of the truncated DSCAM, leading to the rescue of NMDA-R currents. Besides, when endogenous DSCAM expression levels were reduced by expressing a specific shRNA, NR1 expression was also decreased in control iN cells (Supplementary Fig. 5b–e). In addition, reintroducing shRNA-resistant DSCAM in control iN cells in which endogenous DSCAM was knocked down by the specific shRNA restored NR1 expression (Supplementary Fig. 5f–i). Therefore, it is also possible that low expression level of NMDA-Rs by reduced DSCAM levels in ASD iN cells impairs NMDA-R currents, as
previously discussed. In addition, post-synaptic DSCAM can be activated and generate intracellular signals by interacting with FYN kinase [64], which in turn phosphorylates NMDA-Rs to enhance their function [65, 66]. Therefore, a decreased level of NMDA-R expression in ASD iN cells could result in less NMDA-R phosphorylation and reduced currents. Furthermore, DSCAM might play a role as a sensor or linking molecule between Ca\(^{2+}\) and effector molecules. Ligand-receptor binding in spines causes ion channel opening for Ca\(^{2+}\) entry. Ca\(^{2+}\) elevation is spatially restricted to the vicinity of the NMDA-R [67], where sensory molecules, such as the small GTP-binding protein Ras [68] and linking molecules synGAP [69] and RasGRF1 [43] can initiate downstream signaling. We showed that the DSCAM mutation resulted in reduced NMDA-R currents, which could reflect a potential role for DSCAM as a linking molecule to mediate downstream signaling. To validate this, we measured the level of pERK and found a significant reduction in ASD iN cells (Fig. 4). ERK activity in neurons is regulated by diverse extracellular signals via multiple signaling pathways [70]. Agonist binding to the NMDA-R increases post-synaptic Ca\(^{2+}\) [71] and activates the ERK pathway. A reduced pERK level in ASD iN cells further suggests a functional role for DSCAM in NMDA-R-mediated intracellular signaling. Several possibilities exist for how mRNA expression of NMDA-R subunits is decreased in ASD iN cells. First, DSCAM plays a role in organizing NMDA-Rs in dendritic spines by trans-synaptic signaling [25]. DSCAM and other cell adhesion molecules establish the connection between pre- and post-synaptic areas and increase the requirement of NMDA-Rs in spines. Reduction of DSCAM or the presence of truncated N-terminal DSCAM may disturb the trans-synaptic signaling, lowering the demand for NMDA-Rs in spines such that cells produce a smaller number of NMDA-Rs. On the other hand, dendritic levels of DSCAM protein are also regulated by synaptic activity through NMDA-Rs [72]. So, there may be a two-way feedback loop control of NMDA-R expression by DSCAM. Second, the cytoplasmic domain itself or its associated protein of many cell adhesion molecules can translocate to the nucleus to regulate gene expression as a transcriptional regulator [73–75]. Therefore, it could be possible that decreased DSCAM levels may interfere with signaling to the nucleus to regulate gene expression including NMDA-R subunits. In fact, the intracellular domain of DSCAM directly interacts with IPOS, a nuclear import protein which translocates to the nucleus, in turn altering the expression of genes associated with synaptic function and neuronal differentiation [75].

In addition to dysregulated NMDA-R-mediated signaling in ASD iN cells (Fig. 4), we also found downregulation for genes regulating axon development in our RNA sequencing analysis (Fig. 2) with reduced axonal length, but similar dendritic arborization and spine density in ASD iN cells as compared to control (Supplementary Figs. 3 and 7d). Previously, Bruce et al. [76] reported that DSCAM is a potent promoter of axonal outgrowth and in cultures from Dscam\(^{−/−}\) mice, axon outgrowth from the retinal explants was decreased significantly which is consistent with our findings. Others also reported the role of DSCAM in axonal growth, fasciculation, and pathfinding and dendritic field organization in Drosophila [23, 77] and mice [78, 79]. We studied human-iN cells with a DSCAM mutation in this regard to provide more valuable insights on the role of DSCAM to regulate neuronal growth and maturation.

We then used the Dscam-knockout mouse model to further elucidate the function of DSCAM in ASD pathogenesis. Several Dscam KO mice have been reported [37, 80, 81], but social behaviors have not been examined in these mice, partly due to their poor viability against certain genetic backgrounds. We crossed Dscam floxed exon 1 mice (B6.129P2-Dscam\(^{tm.176Oy}\)) with Nestin-Cre mice to generate a conditional Dscam\(^{−/−}\) KO mouse model. This neural stem cell-specific Dscam heterozygous KO mouse showed no gross morphological changes but had deficits in some social interaction behaviors including sociability and social novelty (Fig. 5). However, social communication, as measured by ultrasonic vocalization test, and repetitive behaviors were not altered in Nestin-Dscam\(^{−/−}\)−/− mice as compared to WT littermates (Supplementary Fig. 9). These results are reminiscent of Chromodomain-helicase-DNA-binding protein 8 (Chd8)-deficient mice, in which social behaviors are defective but repetitive behaviors are normal [82], and they recapitulate the behaviors of our ASD patient, who has a score of 14 in social interaction score and a score of 1 in restricted and repetitive behavior in the ADOS-2. We also detected reduced Dscam expression in mouse neurons (Supplementary Fig. 8) of Nestin-Dscam\(^{−/−}\)−/− mice consistent with the findings in human heterozygous neurons derived from our ASD patient. These data suggest that the reduced expression of Dscam itself, which is abnormal, is sufficient to elicit an impaired behavioral phenotype in heterozygous Nestin-Dscam KO mice. The NMDA/AMPA ratio was reduced in glutamatergic neurons of the ACC in Nestin-Dscam\(^{−/−}\)−/− mice (Fig. 5), consistent with the decreased NMDA-R currents observed in ASD iN cells (Fig. 3).
Taken together, these results suggest that the NMDA-R functional change might be a critical mechanism in DSCAM mutation-related ASD.

In summary, by using human ASD patient-derived iN cells and a Dscam mutant mouse model, we revealed a novel ASD pathophysiology in that the DSCAM mutation may lead to autistic phenotypes by impairing NMDA-R function.

REFERENCES

1. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 5th edn. Arlington, VA: American Psychiatric Association; 2013.

2. Wen Z, Christian KM, Song H, Ming GL. Modeling psychiatric disorders with patient-derived iPSCs. Curr Opin Neurobiol. 2016;36:118–27.

3. Wang X, Christian KM, Song H, Ming GL. Synaptic dysfunction in complex psychiatric disorders: from genetics to mechanisms. Genome Med. 2018;10:9.

4. Ben-Reuven L, Reiner O. Modeling the autistic cell: iPSCs recapitulate developmental principles of syndromic and nonsyndromic ASD. Dev Growth Differ. 2016;58:881–91.

5. Lim CS, Yang JE, Lee YK, Lee K, Lee JA, Kaang BK. Understanding the molecular basis of autism in a dish using hiPSC-derived neurons from ASD patients. Mol Brain. 2015:8:57.

6. Zoghbi HY, Bear MF. Synaptic dysfunction in neurodevelopmental disorders associated with autism and intellectual disabilities. Cold Spring Harb Perspect Biol. 2012;4:3.

7. Bourgeron T. From the genetic architecture to synaptic plasticity in autism spectrum disorder. Nat Rev Neurosci. 2015;16:551–63.

8. An JY, Cristina AS, Zhao Q, Edson J, Williams SM, Ravine D, et al. Towards a molecular characterization of autism spectrum disorders: an exome sequencing and systems approach. Transl Psychiatry. 2014;4:e394.

9. Ebrahimi-Fakhari D, Sahin M. Autism and the synapse: emerging mechanisms and mechanism-based therapies. Curr Opin Neurol. 2015;28:91–102.

10. Won H, Lee HR, Gee HY, Mah W, Kim Ji, Lee J, et al. Autistic-like social behaviour in Shank2-mutant mice improved by restoring NMDA receptor function. Nature. 2012;486:261–5.

11. Espinosa F, Xuan Z, Liu S, Powell CM. Neureilgin 1 modulates striatal glutamatergic neurotransmission in a pathway and NMDAR subunit-specific manner. Front Synaptic Neurosci. 2015;7:11.

12. Blundell J, Blaisse CA, Etherton MR, Espinosa F, Tabuchi K, Walz C, et al. Neureilgin-1 deletion results in impaired spatial memory and increased repetitive behavior. J Neurosci. 2010;30:2115–29.

13. Yoo J, Bakes J, Bradley C, Collingridge GL, Kaang BK. Shank mutant mice as an animal model of autism. Philos Trans R Soc Lond B Biol Sci. 2014;369:20130143.

14. Blanton MG, Lo Turco JJ, Kriegstein AR. Endogenous neurotransmitter activates N-methyl-D-aspartate receptors on differentiating neurons in the mouse retina through cell death and restriction of dendrite. J Neurosci. 2010;27:40 mV. The NMDA/AMPA ratio was significantly decreased in Nestin-Dscam+/− mice as compared to WT littermates (WT: n = 33/4 animals, KO: n = 31/4 animals, Mann–Whitney test, ***p < 0.001).

15. Fig. 5 Nestin-Dscam−/− mice exhibit impaired social behaviors. a The total duration of reciprocal interactions was significantly decreased in Nestin-Dscam−/− mice compared to WT littermates (WT: n = 7, KO: n = 7, unpaired t-test, **p < 0.01). b–d Duration of following, nose-poking, and sniffing behaviors in WT and Nestin-Dscam−/− mice. Time spent on following behavior (b) but not nose-poking (c) and sniffing (d) behaviors was significantly decreased in Nestin-Dscam−/− mice as compared to WT littermates (WT: n = 7, KO: n = 7, unpaired t-test, *p < 0.05, ns, not significant). e, f The three-chamber test was used to measure changes in sociability and social novelty in Nestin-Dscam−/− mice. e Percent time in contact with the stranger 1 mouse was significantly increased as compared to the object in WT mice but not in Nestin-Dscam−/− mice (WT: n = 9, KO: n = 7, unpaired t-test, ***p < 0.001, ns, not significant). f In the social novelty test, Nestin-Dscam−/− mice showed no preference between the stranger 1 and stranger 2 mice, whereas WT littermates spent more time in contact with the stranger 2 as compared to stranger 1 mouse (WT: n = 9, KO: n = 7, unpaired t-test, ***p < 0.001, ns, not significant). g, h AMPA-R and NMDA-R currents were estimated in the presence of picrotoxin (50 µM) by varying holding potentials from −70 to −40 mV. The NMDA/AMPA ratio was significantly reduced in Nestin-Dscam+/− mice as compared to WT littermates (WT: n = 33/4 animals, KO: n = 31/4 animals, Mann–Whitney test, ***p < 0.001).
22. Maynard KR, Stein E. DSCAM contributes to dendrite arborization and spine formation in the developing cerebral cortex. J Neurosci. 2012;32:16637–50.

23. Hattori D, Millard SS, Wojtowicz WM, Zipsrly SL. Dscam-mediated cell recognition regulates neural circuit formation. Annu Rev Cell Dev Biol. 2008;24:597–620.

24. Lowe SA, Hodge JJL, Usowicz MM. A third copy of the down syndrome cell adhesion molecule (Dscam) causes synaptic and locomotor dysfunction in dysphoria. Neurobiol Dis. 2018;110:93–101.

25. Li HL, Huang BS, Vishwasrao H, Sutedja N, Chen W, Jin I, et al. Dscam mediates remodeling of glutamate receptors in Aplysia during de novo and learning-related synapse formation. Neuron. 2009;61:527–40.

26. Xu Y, Ye H, Shen Y, Xu Q, Zhu L, Liu J, et al. Dscam mutation leads to hydrocephalus and decreased motor function. Cell Front. 2019;13:385.

27. Okita K, Matsumura Y, Sato Y, Okada A, Morizane A, Okamoto S, et al. A more efficient method to generate integration-free human iPSC cells. Nat Methods. 2011;8:409–12.

28. Zhang Y, Pak C, Han Y, Ahlenius H, Zhang Z, Chanda S, et al. Rapid single-step induction of functional neurons from human pluripotent stem cells. Neur. 2013;27:785–98.

29. Lee YK, Hwang SK, Yang JE, Kwak JH, Seo H, et al. Cohen syndrome patient iPSC-derived neurons and forebrain-like glutamatergic neurons reveal reduced proliferation of neural progenitor cells and altered expression of synapse genes. J Clin Med. 2020;9:1886.

30. Anders S, Huber W. Differential expression analysis for sequence count data. Genome Biol. 2010;11:R106.

31. Zhou Y, Zhou B, Pache L, Chang M, Khodabakhshi AH, Tanaseichuk O, et al. Cohen syndrome: genetic and clinical features in childhood neurodevelopmental disorders: autism spectrum disorders and fragile x syndrome. Curr Neuropharmacol. 2014;12:71–98.

32. Posey DJ, Kem DL, Swiezy NB, Sweeten TL, Wiegang RE, McDougle CJ. A pilot study of D-cycloserine in subjects with autism spectrum disorder. Am J Psychiatry. 2004;161:2115–7.

33. Urbanova M, Oklava L, Manser P, Hartmann K, Herndon A, Deutch S. A trial of D-cycloserine to treat stereotypes in older adolescents and young adults with autism spectrum disorder. Clin Neuropharmacol. 2014;37:69–72.

34. Burket JA, Benson AD, Tang AH, Deutch S. D-cycloserine improves sociability in the BTBR T+itpr3tf/J mouse model of autism spectrum disorders with altered Ras/Raf/ERK1/2 signaling. Brain Res Bull. 2013;96:62–70.

35. Deutch S, Burket JA, Jacome LF, Cannon CR, Herndon AR. D-cycloserine improves the impaired sociability of the Balb/c mouse. Brain Res Bull. 2011;84:8–11.

36. Arvanitis S, Brozov J, Bakken TE, Gleen C, Crawford JJ, Gaspar HA, et al. Genetic identification of brain cell types underlying schizophrenia. Nat Genet. 2018;50:825–33.

37. Groveneman BR, Feng S, Fang QX, Pfeuser M, Lin SX, Blinkiewicz EA, et al. The regulation of N-methyl-D-aspartate receptors by Src kinase. FEBS J. 2012;279:28–38.

38. Wang Q, Guo ML, Jin DZ, Xue B, Fibuch EE, Mao LM. Roles of subunit phosphorylation in regulating glutamate receptor function. Eur J Pharmacol. 2014;728:183–97.

39. Hardingham GE, Arnold FJ, Bading H. Calcium signaling controls CREB-mediated gene expression triggered by synaptic activity. Nat Neurosci. 2017;20:586–84. e523

40. Chen J, Chen Q, Ren K, Feng D, Mao H, et al. Anterior cingulate cortex dysfunction underlies social deficits in Shank2 mutant mice. Nat Neurosci. 2019;22:1223–33.

41. Jung KB, Lee H, Son YS, Lee MO, Kim YD, Oh SJ, et al. Interleukin-2 induces the transcriptional control of excitatory and inhibitory neuronal activity in the ACC. Mol Brain. 2015;8:81.

42. Arvanitis S, Brozov J, Bakken TE, Gleen C, Crawford JJ, Gaspar HA, et al. Genetic identification of brain cell types underlying schizophrenia. Nat Genet. 2018;50:825–33.

43. Groveneman BR, Feng S, Fang QX, Pfeuser M, Lin SX, Blinkiewicz EA, et al. The regulation of N-methyl-D-aspartate receptors by Src kinase. FEBS J. 2012;279:28–38.

44. Wang Q, Guo ML, Jin DZ, Xue B, Fibuch EE, Mao LM. Roles of subunit phosphorylation in regulating glutamate receptor function. Eur J Pharmacol. 2014;728:183–97.

45. Hardingham GE, Arnold FJ, Bading H. Nuclear calcium signaling controls CREB-mediated gene expression triggered by synaptic activity. Nat Neurosci. 2017;20:586–84. e523

46. C.-S. Lim et al.
ACKNOWLEDGEMENTS

We are grateful to Yongmin Sung for technical assistance. This work was supported by the National Honor Scientist Program (NRF-2012R1A3A1050385) through a grant to B-KK; NRF-2016R1D1A1B03931525 and NRF-2020M3ESD9079914 to C-SL; and NRF-2020R1A2C2005021 and NRF-2020M3ESD90799908 to J-AL; and NRF-2017R1A3A1078210 and NRF-2019R1F1A1063932 to KL.

COMPETING INTERESTS

The authors declare no competing interests.

ADDITIONAL INFORMATION

Supplementary information The online version contains supplementary material available at https://doi.org/10.1038/s41380-021-01216-9.

Correspondence and requests for materials should be addressed to K.L., J.-A.L. or B.-K.K.

Reprints and permission information is available at http://www.nature.com/reprints

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

© The Author(s) 2021